Literature DB >> 10456655

Cancer gene and immunotherapy: recent developments.

P Jantscheff1, R Herrmann, C Rochlitz.   

Abstract

Gene and immunotherapeutic approaches to treat human malignant tumors are reviewed. Special attention is given to the different strategies of cancer gene therapy and to recent aspects of cytokine-supported tumor immunotherapy or tumor-specific vaccination. The limitations of these therapy approaches are critically discussed especially with respect to immune escape mechanisms.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10456655     DOI： 10.1007/bf02785840

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  109 in total

Review 1.  Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes.

Authors:  T J Braciale; L A Morrison; M T Sweetser; J Sambrook; M J Gething; V L Braciale
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

2.  MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.

Authors:  B Lethé; P van der Bruggen; F Brasseur; T Boon
Journal:  Melanoma Res       Date:  1997-08       Impact factor: 3.599

3.  TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective.

Authors:  J C Shepherd; T N Schumacher; P G Ashton-Rickardt; S Imaeda; H L Ploegh; C A Janeway; S Tonegawa
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

4.  Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.

Authors:  K Wiechen; C Zimmer; M Dietel
Journal:  Cancer Gene Ther       Date:  1998 Jan-Feb       Impact factor: 5.987

5.  Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.

Authors:  A Mackensen; H Veelken; M Lahn; S Wittnebel; D Becker; G Köhler; P Kulmburg; U Brennscheidt; F Rosenthal; B Franke; R Mertelsmann; A Lindemann
Journal:  J Mol Med (Berl)       Date:  1997-04       Impact factor: 4.599

6.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

Authors:  M L Salgaller; F M Marincola; J N Cormier; S A Rosenberg
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

Review 7.  Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

Authors:  H Tahara; M T Lotze
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.